Biotech Investing
Valirx Share Price: Latest Updates & Investment Insights
Explore the latest Valirx share price movements, financial performance, and expert analysis. Make informed investment decisions with our in-depth guide.
ATXI Stock Analysis: Avenue Therapeutics 2026 Outlook
Is ATXI stock a speculative buy after its Nasdaq delisting? Dive deep into Avenue Therapeutics' Q1 2026 earnings, its Duke license, and the Axsome deal.
Novacyt Share Price Outlook: Post-COVID Pivot & 2026 Catalysts
Is Novacyt a buy in 2026? Read our comprehensive analysis of the Novacyt share price, the Southern Cross Diagnostics acquisition, and FY2025 results.
Atos Share Price: 2026 Outlook and Ticker Confusion Explained
Confused by the Atos share price? Discover the difference between France's Atos SE and NASDAQ's Atossa Therapeutics, plus a complete 2026 financial analysis.
ADMA Stock Analysis: Navigating 2026 Volatility & Guidance Cuts
Is ADMA stock a beaten-down buy or a risky value trap? Deep dive into ADMA Biologics' 2026 earnings, short-seller claims, and ASCENIV growth.
What Happened to SESN Stock? The Sesen Bio & CARM Story
Wondering what happened to SESN stock? Discover the complete story of Sesen Bio's merger, the 1-for-20 reverse split, CVR payouts, and the current status.
SEEL Stock Collapse: What Happened to Seelos Therapeutics?
Wondering what happened to SEEL stock? Discover the timeline of Seelos Therapeutics' clinical trials, Nasdaq delisting, Chapter 11 bankruptcy, and asset sale.
INO Stock Analysis: Can Inovio's October PDUFA Spark a Rebound?
Is INO stock a buy ahead of its crucial October 30, 2026 FDA PDUFA date? Discover Inovio's pipeline, financials, and risks in our expert analysis.
NRXP Stock Forecast: Can NRx Pharmaceuticals Soar in 2026?
Is NRXP stock a buy? Get an expert look at NRx Pharmaceuticals' 2026 pipeline catalysts, KETAFREE FDA timeline, and path to commercialization.
CLVS Stock: The Rise, Fall, and Lessons of Clovis Oncology
Wondering what happened to CLVS stock? Discover the history of Clovis Oncology, the CLVSQ bankruptcy timeline, CVR details, and how to write off losses.
ASRT Stock: Decoding the $23.50 Zydus Buyout and Your Next Move
Assertio Holdings (ASRT) stock is in the midst of a massive M&A bidding war. Discover the details of the Zydus acquisition, the Garda termination, and next steps.
CRXT Stock: The Ultimate Post-Mortem of Clarus Therapeutics
What happened to CRXT stock? Discover the full history of Clarus Therapeutics, the CRXTQ bankruptcy, the sale of Jatenzo, and the latest 2026 lawsuits.
Biogen Share Price: Pipeline Shifts, M&A, and 2026 Outlook
Is the Biogen share price a buy after recent trial misses and the $5.6B Apellis deal? Discover BIIB earnings, pipeline catalysts, and 2026 stock forecasts.
AMRS Stock: What Happened to Amyris and Is There Any Value?
Wondering what happened to AMRS stock? Read our complete guide to the Amyris bankruptcy, shareholder wipeout, and the future of the private Amyris 2.0.
CTIC Stock: What Happened to CTI BioPharma & How to Invest Now
Looking for CTIC stock? Discover what happened to CTI BioPharma, its $1.7B buyout by Sobi, and how to invest in its blockbuster drug Vonjo today.
Cassava Sciences Stock: What Happened to SAVA (and the Pivot to FLNA)?
Looking for Cassava Sciences stock? SAVA has rebranded to Filana Therapeutics (FLNA). Learn what happened to Simufilam, the SEC/DOJ outcomes, and whether FLNA is a buy today.
What Happened to ADMP Stock? Adamis Pharmaceuticals Collapse
Curious about the fate of ADMP stock? Discover the full timeline of Adamis Pharmaceuticals, the DMK merger, SEC fraud charges, bankruptcy, and what's next.
Synairgen Share Price: From AIM Sensation to Liquidation
Tracking the Synairgen share price? Discover how the LSE:SNG biotech delisted from AIM, terminated its INVENT study, and is winding down in 2026.
ADTX Stock: Dilution Trap or Speculative Biotech Play?
Is ADTX stock a speculative goldmine or a dilution trap? Explore Aditxt's financials, Nasdaq delisting battles, and business portfolio in this deep-dive.
Is Roche Stock a Buy? RHHBY Dividends and 2026 Pipeline Forecast
Analyze Roche stock (RHHBY/ROG) in 2026. Discover its 3% dividend yield, Q1 earnings, and emerging obesity, oncology, and digital diagnostics pipelines.
Sareum Share Price: Can the SDC-1801 Pipeline Spark a Rally?
Considering a position in LON:SAR? Read our deep-dive analysis of the Sareum share price, current SDC-1801 trial milestones, financials, and key 2026 catalysts.
BIOR Stock: What Happened to Biora Therapeutics?
Wondering what happened to BIOR stock? Discover the truth about Biora Therapeutics' bankruptcy, the Nasdaq delisting, and what it means for shareholders.
XBI Stock Price Analysis: Is This Equal-Weight Biotech ETF a Buy?
Track the XBI stock price and discover why this equal-weight biotech ETF is a high-beta favorite. Learn about its holdings, risks, and market outlook.
CYDY Stock: CytoDyn's 2026 Breakthroughs, Pipeline & Risks
Is CYDY a buy in 2026? Discover CytoDyn’s latest AACR oncology data, the leronlimab pipeline, financial struggles, and what lies ahead for investors.
Novavax Share Price: Inside the Asset-Light Biotech Turnaround
Is the Novavax share price a deep value buy? Analyze NVAX's historic pivot to high-margin licensing deals with Sanofi and Pfizer, plus its 2026 outlook.
SAVA Stock Rebrand & Forecast: Is Filana Therapeutics (FLNA) a Buy?
Looking for SAVA stock news? Cassava Sciences has officially rebranded as Filana Therapeutics (FLNA). Read our deep dive into the pivot, trials, and forecast.
Merck Stock Price Analysis: 2026 Growth and Pipeline Outlook
Analyze the Merck stock price outlook for 2026. Discover how earnings, the Keytruda patent cliff, and fresh oncology pipeline data impact MRK.
What Happened to SPPI Stock? Complete Guide for Shareholders
Wondering what happened to SPPI stock? Discover the truth behind the Assertio merger, failed CVRs, and how to claim your share of the $15.95M settlement.
AVCT Stock: Avacta LSE Clinical Growth vs. AVCTQ Legacy Case
Wondering what is happening with AVCT stock? Learn about Avacta Group PLC (LSE: AVCT) 2026 clinical breakthroughs and the final status of AVCTQ bankruptcy.
Vaxart Stock (VXRT) Analysis: Can Oral Vaccines Power a Turnaround?
Vaxart stock (VXRT) is at a historic crossroads. Explore the 2026 proxy battle, the Sanofi-backed Dynavax deal, and upcoming Phase 2b clinical data.
Veru Stock Forecast: Can Enobosarm Capitalize on the GLP-1 Boom?
Looking at Veru stock (NASDAQ: VERU)? Discover if this clinical-stage biopharma's muscle-preserving obesity therapy is a buy, sell, or hold for 2026.
MNMD Stock: Definium Rebrand, 2026 Catalysts, and Price Forecast
Analyzing MNMD stock (now DFTX) post-rebrand to Definium Therapeutics. Get the latest on clinical trial catalysts, analyst targets, and 2026 forecasts.
GOVX Stock Analysis: Speculation vs. Phase 3 Reality
Is GOVX stock a buy? Get an expert look at GeoVax Labs' upcoming Phase 3 trials, financial metrics, recent 1-for-25 split, and dilution risks.
Ocugen Stock (OCGN) Forecast: 2026 Catalysts & Financials
Should you buy Ocugen stock? Explore our comprehensive OCGN analysis covering the $130M cash runway extension, Q1 2026 earnings, and gene therapy pipeline.
Bavarian Nordic Stock Analysis: Is BAVA a Buy in 2026?
An expert analysis of Bavarian Nordic stock (BAVA). Explore updated 2026 guidance, Jynneos contract wins, and VIMKUNYA launch potential.
TTOO Stock: What Happened to T2 Biosystems? (2026 Update)
Wondering what happened to TTOO stock? Read our deep dive into T2 Biosystems' Nasdaq delisting, its 2026 liquidation, and what this means for shareholders.
OCGN Stock: Is Ocugen a Buy or Sell After Q1 2026 Pipeline Surge?
Is OCGN stock a buy? Learn about Ocugen's Q1 2026 clinical data, OCU400 Phase 3 updates, the $130M capital infusion, and Wall Street's $9.75 price targets.
Gilead Stock Analysis: HIV Growth, M&A Surge, and Dividend Yield
Is Gilead stock a buy in 2026? Explore GILD's $16B M&A blitz, Q1 earnings beat, massive HIV franchise growth, and reliable dividend profile in our analysis.
Illumina Stock (ILMN): Is the Genomic Giant Finally a Buy?
Is Illumina stock a buy after raising its 2026 outlook? Explore our in-depth ILMN stock analysis covering Q1 earnings, China risks, and NovaSeq X growth.